Intech Investment Management LLC Has $1.57 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Intech Investment Management LLC boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 224.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 42,156 shares of the company’s stock after purchasing an additional 29,167 shares during the period. Intech Investment Management LLC’s holdings in Amphastar Pharmaceuticals were worth $1,565,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of AMPH. Pacer Advisors Inc. grew its stake in Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after buying an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp grew its stake in Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after buying an additional 439,281 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $9,268,000. Hotchkis & Wiley Capital Management LLC acquired a new stake in Amphastar Pharmaceuticals during the third quarter worth about $10,804,000. Finally, Portolan Capital Management LLC grew its stake in Amphastar Pharmaceuticals by 201.1% during the third quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock worth $15,906,000 after buying an additional 218,901 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMPH. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Trading Up 1.4 %

AMPH opened at $28.29 on Friday. The company’s 50 day moving average is $31.91 and its 200-day moving average is $40.57. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.35 billion, a P/E ratio of 9.43, a PEG ratio of 2.19 and a beta of 0.77.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.